Trial · NCT03369236
Results by group31
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 31
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline In Composite Biopsy Score At Week 28 | Danicopan (Double-blind Treatment Period) | Baseline | 11.7 | Standard Deviation 4.23 | score on a scale |
| Change From Baseline In Composite Biopsy Score At Week 28 | Placebo (Double-blind Treatment Period) | Baseline | 9.3 | Standard Deviation 3.50 | score on a scale |
| Change From Baseline In Composite Biopsy Score At Week 28 | Danicopan (Double-blind Treatment Period) | Week 28 | 9.2 | Standard Deviation 4.87 | score on a scale |
| Change From Baseline In Composite Biopsy Score At Week 28 | Placebo (Double-blind Treatment Period) | Week 28 | 10.7 | Standard Deviation 3.39 | score on a scale |
| Change From Baseline In Composite Biopsy Score At Week 28 | Danicopan (Double-blind Treatment Period) | Change from Baseline | -2.0 | Standard Deviation 1.87 | score on a scale |
| Change From Baseline In Composite Biopsy Score At Week 28 | Placebo (Double-blind Treatment Period) | Change from Baseline | 1.3 | Standard Deviation 2.88 | score on a scale |
| Participants With Reduction In Proteinuria At Week 28 | Danicopan (Double-blind Treatment Period) | 0 | participants | ||
| Participants With Reduction In Proteinuria At Week 28 | Placebo (Double-blind Treatment Period) | 1 | participants | ||
| Change From Baseline In Proteinuria At Week 28 | Danicopan (Double-blind Treatment Period) | Baseline | 6137.67 | Standard Deviation 2904.359 | mg/day |
| Change From Baseline In Proteinuria At Week 28 | Placebo (Double-blind Treatment Period) | Baseline | 4274.47 | Standard Deviation 2992.819 | mg/day |
| Change From Baseline In Proteinuria At Week 28 | Danicopan (Double-blind Treatment Period) | Week 28 | 5301.75 | Standard Deviation 2984.445 | mg/day |
| Change From Baseline In Proteinuria At Week 28 | Placebo (Double-blind Treatment Period) | Week 28 | 5186.80 | Standard Deviation 4069.279 | mg/day |
| Change From Baseline In Proteinuria At Week 28 | Danicopan (Double-blind Treatment Period) | Change from Baseline | 302.00 | Standard Deviation 764.211 | mg/day |
| Change From Baseline In Proteinuria At Week 28 | Placebo (Double-blind Treatment Period) | Change from Baseline | 182.20 | Standard Deviation 994.558 | mg/day |
| Percent Change From Baseline In Proteinuria At Week 28 | Danicopan (Double-blind Treatment Period) | 12.5 | Standard Deviation 31.11 | percent change | |
| Percent Change From Baseline In Proteinuria At Week 28 | Placebo (Double-blind Treatment Period) | -10.4 | Standard Deviation 31.35 | percent change | |
| Slope Of Estimated Glomerular Filtration Rate (eGFR) From Baseline To 6 Months | Danicopan (Double-blind Treatment Period) | -2.26840 | Standard Deviation 1.790814 | mL/min/1.73 m^2 per month | |
| Slope Of Estimated Glomerular Filtration Rate (eGFR) From Baseline To 6 Months | Placebo (Double-blind Treatment Period) | -1.45421 | Standard Deviation 2.228395 | mL/min/1.73 m^2 per month | |
| Slope Of Estimated Glomerular Filtration Rate (eGFR) After Open-label Danicopan Treatment | Danicopan (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period | -1.02556 | Standard Deviation 1.389128 | mL/min/1.73 m^2 per month | |
| Slope Of Estimated Glomerular Filtration Rate (eGFR) After Open-label Danicopan Treatment | Placebo (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period) | -1.84935 | Standard Deviation 3.506810 | mL/min/1.73 m^2 per month |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03369236/results